Team
Nabil specialises in IP and regulatory advice for clients ranging from start-ups to global players, with a particular focus on the life sciences and other technology-rich sectors.
Nabil provides pragmatic, commercially-minded advice with a focus on intellectual property strategy and regulatory compliance. In addition to advice on the identification, protection, commercialisation and enforcement of IP rights, Nabil supports clients with commercial contracts, due diligence, and regulatory compliance.
Prior to training as a solicitor, Nabil worked in early phase pharmaceutical R&D for AstraZeneca and chaired the Physical Organic Chemistry Group of the Royal Society of Chemistry.
Since 2021 | Senior Associate, Taylor Wessing |
2020 - 2021 | Associate, Taylor Wessing |
2018 - 2020 | Associate, Eversheds Sutherland |
2016 - 2017 | Senior solicitor, Hempsons |
2014 - 2016 | In-house counsel, International Procurement and Logistics |
2012 - 2014 | Trainee, Kempner & Partners |
2005 - 2008 | Associate team leader, AstraZeneca |
2003 - 2005 | R&D chemist, Avecia |
2001 - 2003 | Post-Doctoral Research Fellow, University of Groningen |
2014 | Admitted as a solicitor |
2013 | LLM, BPP Law School |
2011 | LPC, BPP Law School |
2010 | GDL, BPP Law School |
2002 | PhD, Cambridge University |
1997 | BSc (Hons) Medicinal Chemistry, University of Leeds |
Aktuelle News & Insights
Global pharma groups Eli Lilly and AbbVie withdraw from UK’s branded medicines voluntary scheme
von Nabil Asaad, PhD und Lauren Mounteney
Using quantum computing in life sciences
Nabil Asaad looks at the potential for quantum computing to revolutionise life sciences.
von Nabil Asaad, PhD
2 von 4 Insights
Advising IP Group on option exercise to accelerate development of first-in-class gene therapy for patients with cystic fibrosis
von Colin McCall und Nabil Asaad, PhD
Ross McNaughton recognised in The Lawyer's 2023 Hot 100
von Ross McNaughton